Six hundred sixty-nine patients enrolled (35 UK centers, 2008-2014); mean tumor size was 2.9 cm, and 358 (54%) were low risk (< 4 cm, no rete testis invasion). With a median follow-up of 72 months, 82 ...
Contrast-enhanced in-phase Dixon sequence could reduce the need for correlation among other imaging modalities to better identify areas of prior biopsy during breast MRI interpretation, according to a ...
Final outcomes comparing acute grade ≥2 genitourinary toxicity following MRI- vs. CT-guided prostate SBRT presented at ASTRO 2022 Final outcomes of the phase III randomized trial comparing acute grade ...
According to ARRS' American Journal of Roentgenology (AJR), the contrast-enhanced in-phase Dixon sequence could reduce the need for correlation among other imaging modalities to better identify areas ...
BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...
For more than 60 years, the medical community has been refining the diagnosis of multiple sclerosis. The diagnosis of ...
ViewRay: Phase III Interim Data Show Superiority Of MRIdian MRI-guidance In SBRT For Prostate Cancer
(RTTNews) - ViewRay Inc. (VRAY) said interim data from the single center Phase III randomized MIRAGE trial, which compared MRIdian MRI-guided vs. CT-guided Stereotactic Body Radiotherapy or SBRT for ...
Telix Pharmaceuticals Limited (NASDAQ:TLX) is among the best stocks with the highest upside potential. On September 10, 2025, Telix Pharmaceuticals Limited (NASDAQ:TLX) announced the dosing of the ...
Final clinical and pharmacokinetic (PK) results from a phase 1 study of the novel N-cadherin (N-cad) antagonist, Exherin (ADH-1), in patients with refractory solid tumors stratified according to N-cad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback